

Revision date: 30-Mar-2012

Version: 1.0

Page 1 of 6

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com Pfizer Ltd **Ramsgate Road** Sandwich, Kent CT13 9NJ **United Kingdom** +00 44 (0)1304 616161 Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Vinorelbine Tartrate Injection

Trade Name:	Not established
Chemical Family:	Semi-Synthetic Vinca Alkaloid
Intended Use:	Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Appearance: Signal Word:	Colorless to pale yellow solution WARNING
Statement of Hazard:	Suspected of damaging the unborn child. Suspected of causing genetic defects.
Additional Hazard Information: Long Term: Known Clinical Effects: EU Indication of danger:	Animal studies have shown a potential to cause adverse effects on the fetus. Bone marrow suppression is the most serious adverse effect seen during clinical use. Adverse effects most commonly reported in clinical use include decreased red blood cell count (anemia), neutropenia, thrombocytopenia, inflammation of the mouth (stomatitis), nausea, liver enzyme changes, fatigue, allergic reaction. Toxic to reproduction, Category 2 Mutagenic: Category 2

EU Hazard Symbols:



EU Risk Phrases:

Australian Hazard Classification (NOHSC):

R46 - May cause heritable genetic damage. R61 - May cause harm to the unborn child. Hazardous Substance. Non-Dangerous Goods.

Material Name: Vinorelbine Tartrate Injection Revision date: 30-Mar-2012

Page 2 of 6 Version: 1.0

2. HAZARDS IDENTIFICATION Note: This docu

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Vinorelbine Tartrate	125317-39-7	Not Listed	Mut. Cat.2;R46 Repr. Cat.2;R61	1

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.

Material Name: Vinorelbine Tartrate Injection Revision date: 30-Mar-2012

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling:Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use
appropriate personal protective equipment (see Section 8). Wash thoroughly after handling.
Releases to the environment should be avoided. Review and implement appropriate technical
and procedural waste water and waste disposal measures to prevent occupational exposure or
environmental releases. Potential points of process emissions of this material to the
atmosphere should be controlled with dust collectors, HEPA filtration systems or other
equivalent controls.Storage Conditions:Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Vinorelbine Tartrate Pfizer Occupational Exposure Band (OEB):	OEB 5 (control exposure to <1ug/m ³)
Engineering Controls:	General room ventilation is adequate unless the process generates dust, mist or fumes. Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section.
Environmental Exposure Controls:	Refer to specific Member State legislation for requirements under Community environmental legislation.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Solution	Color:	Colorless to Pale yellow
Molecular Formula:	Mixture	Molecular Weight:	Mixture

9. PHYSICAL AND CHEMICAL PROPERTIES

10. STABILITY AND REA	CTIVITY	
Chemical Stability: Conditions to Avoid: Incompatible Materials:	Stable under normal conditions of use. Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from strong oxidizers	

11. IOXICOLOGICAL INFORMATIO

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Vinorelbine Tartrate

Mouse Intravenous LD50 28 mg/kg

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Vinorelbine Tartrate

Embryo / Fetal DevelopmentMouseIntravenous 9 mg/m2LOAELEmbryotoxicity, Fetotoxicity, TeratogenicEmbryo / Fetal DevelopmentRabbitIntravenous 5.5 mg/m2LOAELEmbryotoxicity, Fetotoxicity, TeratogenicReproductive & FertilityRatIntravenous 0.22 mg/kg/dayLOAELFertility

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Vinorelbine Tartrate

In Vivo Micronucleus Mouse Positive HGPRT Forward Gene Mutation Assay Positive *In Vivo* Chromosome Aberration Hamster Bone marrow Positive Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Interview Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations. Member State
specific and Community specific provisions must be considered. Considering the relevant
known environmental and human health hazards of the material, review and implement
appropriate technical and procedural waste water and waste disposal measures to prevent
occupational exposure and environmental release. It is recommended that waste minimization
be practiced. The best available technology should be utilized to prevent environmental
releases. This may include destructive techniques for waste and wastewater.

Material Name: Vinorelbine Tartrate Injection Revision date: 30-Mar-2012

Page 5 of 6 Version: 1.0

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: EU Indication of danger:	T Toxic to reproduction, Category 2 Mutagenic: Category 2
EU Risk Phrases:	R46 - May cause heritable genetic damage. R61 - May cause harm to the unborn child.
EU Safety Phrases:	S23 - Do not breathe fumes/vapour/spray. S36/37 - Wear suitable protective clothing and gloves. S53 - Avoid exposure - obtain special instructions before use.

OSHA Label: WARNING Suspected of damaging the unborn child. Suspected of causing genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class: Class D, Division 2, Subdivision A



Water for Injection
Inventory - United States TSCA - Sect. 8(b)
Australia (AICS):
REACH - Annex IV - Exemptions from the
obligations of Register:
EU EINECS/ELINCS List

Present Present Present

231-791-2

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

Material Name: Vinorelbine Tartrate Injection Revision date: 30-Mar-2012

Page 6 of 6 Version: 1.0

R46 - May cause heritable genetic damage.R61 - May cause harm to the unborn child.Data Sources:Publicly available toxicity information. Pfizer proprietary drug development information.

Prepared by:

Product Stewardship Hazard Communication Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet